• About 14 months after inking a natural killer cell deal with Cellectis SA (NASDAQ: CLLS), Cytovia plans to list on NASDAQ via a merger with the SPAC Isleworth Healthcare Acquisition Corp (NASDAQ: ISLE).

• The company went on to create a China joint venture. The biotech teamed up with China-based biotech investor TF Capital to form CytoLynx Therapeutics with $45 million in funding in September 2021.

• Related: Cytovia, Cellectis Expand Collaboration On Gene-Edited Cancer Platform In China.

• The blank-check deal gives Cytovia about $227 million in gross proceeds.

• The transaction would value the combined company at a pro forma equity value of $602 million.

• Isleworth will be renamed Cytovia Therapeutics Inc and start trading on NASDAQ under the ticker INKC.

• The deal will bankroll INDs and initiate Phase 1/2 trials for four assets: CYT-303, CYT-100, CYT-150, and CYT-503.

• Isleworth has also secured an additional $20 million for the deal from new investors.

• Concurrent with the business combination agreement, Cellectis received a $20 million convertible note in payment of the upfront collaboration consideration.

• Price Action: CLLS shares are up 1.89% at $3.77 during the market session on the last check Wednesday.

See more from Benzinga

• Humana Q1 Earnings Beats Expectations, Raises FY22 Profit Guidance

• Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.